Monday of the Eleventh Week in Ordinary Time Reading 1 1

New Post Public Reply Private Reply Replies (0) Message Board
Bible Feed
196
Monday of the Eleventh Week in Ordinary Time

Reading 1 1 Kgs 21:1-16

Naboth the Jezreelite had a vineyard in Jezreel next to the palace of Ahab, king of Samaria. Ahab said to Naboth, “Give me your vineyard to be my vegetable garden, since it is close by, next to my house. I will give you a better vineyard in exchange, or, if you prefer, I will give you its value in money.” Naboth answered him, “The LORD forbid that I should give you my ancestral heritage.” Ahab went home disturbed and angry at the answer Naboth the Jezreelite had made to him: “I will not give you my ancestral heritage.” Lying down on his bed, he turned away from food and would not eat. His wife Jezebel came to him and said to him, “Why are you so angry that you will not eat?” He answered her, “Because I spoke to Naboth the Jezreelite and said to him, ‘Sell me your vineyard, or, if you prefer, I will give you a vineyard in exchange.’ But he refused to let me have his vineyard.” His wife Jezebel said to him, “A fine ruler over Israel you are indeed! Get up. Eat and be cheerful. I will obtain the vineyard of Naboth the Jezreelite for you.” So she wrote letters in Ahab’s name and, having sealed them with his seal, sent them to the elders and to the nobles who lived in the same city with Naboth. This is what she wrote in the letters: “Proclaim a fast and set Naboth at the head of the people. Next, get two scoundrels to face him and accuse him of having cursed God and king. Then take him out and stone him to death.” His fellow citizens—the elders and nobles who dwelt in his city— did as Jezebel had ordered them in writing, through the letters she had sent them. They proclaimed a fast and placed Naboth at the head of the people. Two scoundrels came in and confronted him with the accusation, “Naboth has cursed God and king.” And they led him out of the city and stoned him to death. Then they sent the information to Jezebel that Naboth had been stoned to death. When Jezebel learned that Naboth had been stoned to death, she said to Ahab, “Go on, take possession of the vineyard of Naboth the Jezreelite that he refused to sell you, because Naboth is not alive, but dead.” On hearing that Naboth was dead, Ahab started off on his way down to the vineyard of Naboth the Jezreelite, to take possession of it.

Responsorial Psalm Ps 5:2-3ab, 4b-6a, 6b-7

R. (2b) Lord, listen to my groaning. Hearken to my words, O LORD, attend to my sighing. Heed my call for help, my king and my God! R. Lord, listen to my groaning. At dawn I bring my plea expectantly before you. For you, O God, delight not in wickedness; no evil man remains with you; the arrogant may not stand in your sight. R. Lord, listen to my groaning. You hate all evildoers. You destroy all who speak falsehood; The bloodthirsty and the deceitful the LORD abhors. R. Lord, listen to my groaning.

Alleluia Ps 119:105

R. Alleluia, alleluia. A lamp to my feet is your word, a light to my path. R. Alleluia, alleluia.

Gospel Mt 5:38-42

Jesus said to his disciples: "You have heard that it was said, An eye for an eye and a tooth for a tooth. But I say to you, offer no resistance to one who is evil. When someone strikes you on your right cheek, turn the other one to him as well. If anyone wants to go to law with you over your tunic, hand him your cloak as well. Should anyone press you into service for one mile, go with him for two miles. Give to the one who asks of you, and do not turn your back on one who wants to borrow."
- - -

Lectionary for Mass for Use in the Dioceses of the United States, second typical edition, Copyright © 2001, 1998, 1997, 1986, 1970 Confraternity of Christian Doctrine; Psalm refrain © 1968, 1981, 1997, International Committee on English in the Liturgy, Inc. All rights reserved. Neither this work nor any part of it may be reproduced, distributed, performed or displayed in any medium, including electronic or digital, without permission in writing from the copyright owner.

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Class Action Greenlighted Against Concordia for Title IX Violations

Updated Category News Views 87

Paving the Way for Equality in Campus Sports Ah, courts and colleges—two institutions you'd hope would play by the rules. But here we are, knee-deep in a legal battle with Concordia University Irvine (CUI) caught in the crosshairs of Title IX compliance issues. No surprise there when a federal court finally gave the nod for a class action to plow ahead. Class Action...

Continue Reading
AppLovin Legal Woes: A Deep Dive into Investor Claims

Updated Category News Views 104

AppLovin Faces Legal Heat and Market Scrutiny Bitter truth has a way of crashing like a wave, and AppLovin (NASDAQ: APP) is feeling the brunt of it. Now knee-deep in a securities class action, the firm’s been accused of selling fairy tales about its AI capabilities, leaving investors clutching at substantial losses. If you’ve been banking on their promises between...

Continue Reading
Microsoft's Cloud Misstep: Recovery Plans in Focus

Updated Category News Views 149

Microsoft's Stumble Puts CIOs on Alert Thursday's Microsoft 365 outage, a wrench in the works for every firm that ties its daily operations to these cloud services, has brought some harsh truths to the table. On November 12, outages hit users hard, preventing access to Exchange Online mailboxes and sending ripples through Teams, SharePoint, Copilot, and Defender. You...

Continue Reading
EFICYENT Ventures to Connect at Singapore FinTech Fest

Updated Category News Views 118

Why the Singapore FinTech Festival Matters The world's hardly a stranger to hype, but the Singapore FinTech Festival carries some real weight. From November 18 to 20, 2026, this gig isn't just industry chatter—it's a high-stakes convergence of policymakers, financial institutions, fintech innovators like EFICYENT, and the money folk looking to mold the future of...

Continue Reading
Innovent's Seven Drugs Leap onto 2026 Reimbursement Chart

Updated Category News Views 202

A Bold Move in Biopharmaceuticals Innovent Biologics just pulled a rabbit out of their hat. Seven of their cutting-edge meds made it onto China's National Reimbursement Drug List for 2026. This isn't just a spreadsheet entry—it's a lifeline thrown to patients across the oncology, metabolic, and autoimmune landscapes, as well as a financial booster for Innovent (HKEX:...

Continue Reading
Novo's CagriSema Trial Shows Promising Obesity Results

Updated Category News Views 162

Novo's Latest Weight Loss Gamble Well, look what we have here. Novo Nordisk is shaking up the obesity treatment scene with some bold numbers from their REDEFINE 9 trial. The investigational CagriSema combo of amylin analog and GLP-1 receptor agonist has churned out an eyeball-popping near 21% weight loss. For context, we're staring down the barrel of numbers far meatier...

Continue Reading
Novo's Research Unlocks New Insights into Food Noise

Updated Category News Views 179

Unpacking the Science Behind Food Noise When folks think about losing weight, most picture shedding pounds and fitting into those elusive smaller jeans. But get this—there’s a curveball called ‘food noise’ that’s making waves in obesity treatment. Novo Nordisk’s semaglutide injections are shaking things up, cutting down on those persistent thoughts about food....

Continue Reading
Maritime Safety Urged After New Orleans Vessel Incident

Updated Category News Views 109

The Mississippi River saw a bit of drama near the Port of New Orleans when a river cruise turned into an unexpected rescue operation. Listen up, because incidents like this bring maritime safety right to the forefront; we can't ignore the waters that shape our daily lives here in the Big Easy. Navigating the Waters Safely Some 150 souls found themselves in a pickle when...

Continue Reading
Windward Bio Surges 68% in Nasdaq Debut

Updated Category News Views 134

Windward Bio's Impressive Nasdaq Debut Well, how's that for a debut? Windward Bio, this buzzing clinical-stage biotechnology firm, hit Nasdaq like a storm on November 13, 2026. They priced their IPO at $17.00 per share, but by market close, the stock sat comfortably at $28.50. That's a hearty 68% jump on day one, putting their market value at a sweet $1.69 billion. Behind...

Continue Reading
Ecopetrol Sidesteps Hefty Fines After Investigation Closure

Updated Category News Views 145

Colombian Watchdog Gives Ecopetrol a Pass It's like dodging a bullet in a duel at high noon. The Superintendency of Industry and Commerce (SIC) has finally closed its investigation into Ecopetrol S.A. and its subsidiaries, CENIT and OCENSA, after a probe two years in the making. The stakes were sky-high, folks. We're talkin' about just shy of 530 billion Colombian pesos...

Continue Reading

Top 5 Most Recently Viewed Articles

Kimbell Royalty Partners Engages Investors at Key Conferences

Updated Category News Views 101

Kimbell Royalty Partners to Attend Notable Investor Conferences Kimbell Royalty Partners, LP (NYSE: KRP) is a prominent owner of oil and natural gas mineral and royalty interests. The company proudly manages over 129,000 gross wells across multiple states. In an effort to strengthen investor relations and share its strategic outlook, Kimbell has announced its...

Continue Reading
Karsan's Autonomous Bus Debuts at Efteling Park

Updated Category News Views 72

A Leap Towards Autonomous Mobility What we have here is Karsan breaking new ground again. They've rolled out their Autonomous e-ATAK at Efteling, the famous theme park in the Netherlands. And that's not just any park—it's a place teeming with tourists, a hotspot demanding efficient transport. Yet, these folks aren't just cranking out fancy gadgets for showing off....

Continue Reading
EyePoint Pharmaceuticals Expands Workforce with Stock Options

Updated Category News Views 301

EyePoint Pharmaceuticals Expands Workforce with Stock Options EyePoint Pharmaceuticals, Inc. (Nasdaq: EYPT), a dynamic biopharmaceutical company, is on a mission to enhance the lives of patients facing serious retinal diseases. Recently, the company made a notable announcement regarding the expansion of its team through the granting of non-statutory stock options to new...

Continue Reading
IonQ Shares: Insights Into Their Current Market Performance

Updated Category News Views 204

Overview of IonQ's Current Stock Performance IonQ Inc. IONQ shares have seen a notable decline recently, continuing a downward trend that’s persisted over the last couple of weeks. As the company gears up to announce its second-quarter earnings, investors are closely monitoring the developments, particularly the anticipated shift in stock momentum. Market Sentiment and...

Continue Reading
Exploring the Promising CD47 Inhibitor Drug Market Growth

Updated Category News Views 40

Understanding the CD47 Inhibitor Drug Market Gaining insights into the CD47 inhibitor drug market is crucial for recognizing the changes and advancements in cancer immunotherapy. These drugs play a vital role in the battle against cancer by harnessing the body's immune system to identify and eliminate malignant cells. CD47's Role in Cancer CD47, often referred to as the...

Continue Reading